Stay updated with breaking news from Luigi Manenti. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lixudebart (ALE.F02) is a first-in-class monoclonal antibody in clinical development for multi-organ fibrosis Alentis Therapeutics ("Alentis"), the clinical-stage biotechnology company developing
BASEL, Switzerland--(BUSINESS WIRE)--#CLDN1--Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the appointment of Tony Mok, Professor of Clinical Oncology at the Chinese University of Hong Kong a...
BASEL, Switzerland, August 29, 2023--Late-Breaking Oral Presentation on ALE.F02 as Potential Treatment for Pulmonary Fibrosis
Alentis Therapeutics has received fast track designation from the FDA for ALE.C04 to treat patients with head and neck squamous cell carcinoma.
The FDA has granted fast track designation to ALE.C04 for use as a potential therapeutic option in patients with recurrent or metastatic, Claudin-1–positive head and neck squamous cell carcinomas.